ORAMED PHARMACEUTICALS INC (ORMP)       2  +0.01 (+0.5%)

Hot Stocks: CTSH rises on guidance; LOGI slumps; CAT hits 52-week high; ORMP plunges 76%

CAT set a 52-week high. CTSH rose on guidance and a leadership change. LOGI falls on a weak forecast. ORMP plunged 76% on clinical data.

Why Oramed Pharmaceuticals Stock Is Crashing Today

The company's lead pipeline candidate is still being evaluated as a potential treatment for NASH after a major flop in treating type 2 diabetes.

AVCT Stock Falls as American Virtual Cloud Technologies Files for Bankruptcy

American Virtual Cloud Technologies (AVCT) stock is taking a beating on Thursday as the company, and two subsidiaries, file for bankruptcy.

Why Is Oramed (ORMP) Stock Down 75% Today?

Oramed (ORMP) stock is falling hard Thursday after announcing a Phase 3 clinical trial of its diabetes treatment missed its primary endpoint.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!

Oramed stock slumps ~70% as diabetes drug fails phase 3 study

Oramed Pharmaceuticals' (ORMP) drug ORMD-0801 did not meet the main goal of improving blood sugar levels, compared to placebo in patients with Type 2 Diabetes (T2D) in a phase...

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...

Oramed Letter to Shareholders

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug...

Bullish Two Hundred Day Moving Average Cross - ORMP

Oramed Pharmaceuticals GAAP EPS of -$0.18, revenue of $2.02M (NASDAQ:ORMP)

Oramed Pharmaceuticals press release (ORMP): Q3 GAAP EPS of -$0.18.Revenue of $2.02M (flat Y/Y).As of September 30, 2022, we had approximately $160 million in cash and...

Oramed Reports Third Quarter 2022 Financial Results

/PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company...

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

/PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of...